SCHEMBL23901524

SCHEMBL23901524

Cc1cc(C2CCOCC2)nc2c(C(=O)Nc3ccc(OC(C)C)cc3)ncn12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 4/20 0.41
ALDH1A1 P00352 4/20 0.39
GLA P06280 1/20 0.39
MAT2A P31153 1/20 0.39
MAPT P10636 3/20 0.38
USP2 O75604 1/20 0.38
ALOX15 P16050 1/20 0.38
KMT2A Q03164 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
TP53 P04637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 2/20 0.38
MAPK1 P28482 2/20 0.38
DGAT1 O75907 1/20 0.37
RAF1 P04049 2/20 0.37
POLB P06746 1/20 0.37
ELOVL6 Q9H5J4 2/20 0.37
ELOVL3 Q9HB03 1/20 0.37
NR3C1 P04150 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23901677 0.87 L3MBTL1 (0.45) IRAK4ALDH1A1MAPTHSD17B10TP53
SCHEMBL23901591 0.82 RAB9A (0.43) ALDH1A1MAPTUSP2ALOX15KMT2A
SCHEMBL23901467 0.75 IRAK4 (0.34) IRAK4ALDH1A1HSD17B10MAPK1RAF1
SCHEMBL23901521 0.72 CD38 (0.39)
SCHEMBL23901674 0.70 LMNA (0.38) IRAK4ALDH1A1MAPTKMT2AHSD17B10
SCHEMBL23901679 0.70 RAF1 (0.34) IRAK4ALDH1A1KMT2AHSD17B10KDM4E
SCHEMBL19579040 0.69 MAPT (0.51) ALDH1A1GLAMAPTKMT2ASMN1; SMN2
SCHEMBL19438212 0.68 CNR2 (0.39) ALDH1A1
SCHEMBL17730299 0.67 GBA1 (0.42) ALDH1A1GLAMAPTSMN1; SMN2KDM4E
SCHEMBL23901466 0.67 DEGS1 (0.37) HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2021-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, GBA2 IRAK4 1349/4885ALDH1A1 1121/4885GLA 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.